Clavulanate Potassium

CHEMBL1003 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

237.2 g/mol

LogP

—

Phase

4

The potassium salt form of clavulanic acid, a suicide inhibitor of beta-lactamase enzymes that irreversibly binds to these bacterial enzymes and prevents them from destroying beta-lactam antibiotics. It is combined with amoxicillin or ticarcillin to restore efficacy against beta-lactamase-producing resistant organisms. It has little intrinsic antibacterial activity itself.

Moleküler Ağırlık

237,2500 g/mol

TPSA

89,90 Å²

Terapötik Alanlar

Infectious Disease Bladder Cancer Asthma Chronic Obstructive Pulmonary Disease Chronic Kidney Disease Obesity Lymphoma Tuberculosis Prostate Cancer Leukemia

Etki Mekanizması

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21.[K+]

InChI

InChI=1S/C8H9NO5.K/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4;/h1,6-7,10H,2-3H2,(H,12,13);/q;+1/p-1/b4-1-;/t6-,7-;/m1./s1

Molecular Formula

C8H8KNO5

HBD / HBA

1 / 5

Döndürülebilir Bağlar

2

Ağır Atomlar

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The potassium salt form of clavulanic acid, a suicide inhibitor of beta-lactamase enzymes that irreversibly binds to these bacterial enzymes and prevents them from destroying beta-lactam antibiotics. It is combined with amoxicillin or ticarcillin to restore efficacy against beta-lactamase-producing resistant organisms. It has little intrinsic antibacterial activity itself.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanate Potassium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1003. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 23665591. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Clavulanate Potassium PillFYI'da

Yapı

Hızlı Veriler

Formül: C8H8KNO5
Eş Anlamlılar: 14

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.